Every treatment we track, side by side. Same information, same order, every time.
alectinib
ALK-positive non-small cell lung cancer
brigatinib
ALK-positive metastatic NSCLC
mobocertinib
EGFR exon 20 insertion NSCLC; confirm market status before use
adagrasib
KRAS G12C-mutated NSCLC and selected colorectal cancer contexts
lorlatinib
sotorasib
amivantamab-vmjw
EGFR exon 20 insertion and other EGFR-mutated NSCLC settings
capmatinib
METex14-altered metastatic non-small cell lung cancer
osimertinib
EGFR-mutated non-small cell lung cancer
crizotinib
ALK or ROS1-positive metastatic NSCLC and selected other indications